W
Wilma Barcellini
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 342
Citations - 7464
Wilma Barcellini is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Medicine & Autoimmune hemolytic anemia. The author has an hindex of 39, co-authored 267 publications receiving 5428 citations. Previous affiliations of Wilma Barcellini include University of Milan.
Papers
More filters
Journal ArticleDOI
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
Wilma Barcellini,Bruno Fattizzo,Anna Zaninoni,Tommaso Radice,Ilaria Nichele,Eros Di Bona,Monia Lunghi,C Tassinari,Fiorella Alfinito,Antonella Ferrari,Anna Paola Leporace,Pasquale Niscola,Monica Carpenedo,Carla Boschetti,Nicoletta Revelli,Maria Antonietta Villa,Dario Consonni,Laura Scaramucci,Paolo de Fabritiis,Giuseppe Tagariello,Gianluca Gaidano,Francesco Rodeghiero,Agostino Cortelezzi,Alberto Zanella +23 more
TL;DR: Predictors of a fatal outcome were severe infections, particularly in splenectomized cases, acute renal failure, Evans syndrome, and multitreatment (4 or more lines).
Journal ArticleDOI
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jäger,Wilma Barcellini,Catherine Broome,Morie A. Gertz,Anita Hill,Quentin A. Hill,Bernd Jilma,David J. Kuter,Marc Michel,Marco Montillo,Alexander Röth,Sacha Zeerleder,Sigbjørn Berentsen +12 more
TL;DR: The First International Consensus Group recommended that Corticosteroids remain first-line therapy for warm-AIHA, while the addition of rituximab should be considered early in severe cases and if no prompt response to steroids is achieved.
Journal ArticleDOI
Treatment of autoimmune hemolytic anemias
Alberto Zanella,Wilma Barcellini +1 more
TL;DR: Rituximab is now recommended as first-line treatment in CAD, and additional therapies are intravenous immunoglobulins, danazol, plasma-exchange, and alemtuzumab and high-dose cyclophosphamide as last resort option.
Journal ArticleDOI
Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia
Wilma Barcellini,Bruno Fattizzo +1 more
TL;DR: Hemoglobin defines the clinical severity of hemolysis, and thrombocytopenia suggests a possibleThrombotic microangiopathy or Evans' syndrome, and a comprehensive clinical and laboratory evaluation is advisable for a correct diagnostic and therapeutic workup of the different hemolytic conditions.
Journal ArticleDOI
TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients
Wilma Barcellini,G P Rizzardi,Maria Orietta Borghi,C. Fain,Adriano Lazzarin,Pier Luigi Meroni +5 more
TL;DR: In the course of HIV disease mitogen-stimulated IL-2 production decreased, spontaneous and stimulated IL-6 production and spontaneous IL-10 secretion increased, and a switch from a type 1 to a type 2 response occurs in HIV infection.